ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.320,96
0,33%
S&P 500
5.631,22
0,28%
US Dollar vs BRL
5,44884
0,01%
Bitcoin
63.690,06
-1,79%
Brent Oil
83,255
-1,29%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTAW)

  7. Pasithea Therapeutics Corporation (KTTAW) Notícias

KTTAW

Pasithea Therapeutics (KTTAW)

Pasithea Therapeutics Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KTTAW
DataHoraFonteTítuloCódigoCompanhia
13/06/202407:59GlobeNewswire Inc.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialNASDAQ:KTTAWPasithea Therapeutics Corporation
28/05/202410:05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAWPasithea Therapeutics Corporation
28/05/202410:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTTAWPasithea Therapeutics Corporation
28/05/202407:59GlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
14/05/202418:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAWPasithea Therapeutics Corporation
29/04/202408:59GlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
24/04/202408:59GlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAWPasithea Therapeutics Corporation
13/02/202409:59GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
08/01/202409:59GlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAWPasithea Therapeutics Corporation
02/01/202410:35GlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAWPasithea Therapeutics Corporation
28/12/202319:00GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAWPasithea Therapeutics Corporation
19/12/202319:19GlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
11/12/202310:01GlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAWPasithea Therapeutics Corporation
29/11/202318:27GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAWPasithea Therapeutics Corporation
29/11/202309:59GlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAWPasithea Therapeutics Corporation
09/11/202309:59GlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAWPasithea Therapeutics Corporation
14/09/202309:30GlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Final Results of Tender OfferNASDAQ:KTTAWPasithea Therapeutics Corporation
07/09/202317:14GlobeNewswire Inc.Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
01/08/202308:59GlobeNewswire Inc.Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviNASDAQ:KTTAWPasithea Therapeutics Corporation
20/07/202309:43GlobeNewswire Inc.Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashNASDAQ:KTTAWPasithea Therapeutics Corporation
20/07/202309:40GlobeNewswire Inc.Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.NASDAQ:KTTAWPasithea Therapeutics Corporation
30/06/202310:28GlobeNewswire Inc.Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of DirectorsNASDAQ:KTTAWPasithea Therapeutics Corporation
29/06/202309:29GlobeNewswire Inc.Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
06/06/202317:30GlobeNewswire Inc.Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.NASDAQ:KTTAWPasithea Therapeutics Corporation
01/06/202308:57GlobeNewswire Inc.Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
03/05/202309:26GlobeNewswire Inc.Pasithea Therapeutics to Participate in EF Hutton Inaugural Global ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
02/03/202310:00GlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
23/02/202310:00GlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)NASDAQ:KTTAWPasithea Therapeutics Corporation
16/02/202309:30GlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine AwardNASDAQ:KTTAWPasithea Therapeutics Corporation
18/01/202310:00GlobeNewswire Inc.Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:KTTAW

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
AZEV4
AZEVEDO PN
BOV
AMER3
Americanas ON
BOV
INBR32
Inter &
BOV
GFSA3
GAFISA ON
BOV
AERI3
Aeris Industria E Comerc... ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados